Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Current diagnosis of primary cutaneous ALCL (those with systemic ALCL are eligible)

Received an allogeneic stem cell transplant \<3 months prior to the first dose of study medication, or presence of polymerase chain reaction (PCR)-detectable cytomegalovirus (CMV) in any post-allogeneic transplant participant

Receiving immunosuppressive therapy

Receiving systemic therapy for chronic graft-versus-host disease (topical therapy is allowed)

Previous treatment with any anti-CD30 antibody

Therapeutic monoclonal antibody use within the longer of 6 weeks or 5 plasma half-lives

Systemic cardiac disease that would, in the opinion of the investigator or medical monitor, interfere with assessment of efficacy or safety of the drug

History of another primary malignancy not in remission for at least 3 years (the following are exempt from the 3-year limit: nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear)

Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML

History of cirrhosis

Active systemic viral, bacterial, or fungal infection requiring antimicrobial, antiviral therapy or antifungal therapy within 2 weeks prior to the first dose of study drug (routine antimicrobial prophylaxis is acceptable)

Concurrent therapy with other anti-neoplastic or experimental agents

Systemic corticosteroid therapy \<7 days prior to first dose of the study medication

Any serious underlying medical condition that, in the opinion of the investigator or medical monitor, would impair their ability to receive or tolerate the planned treatment

Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation

Received nitrogen mustard agents, melphalan, or BCNU therapy within 6 weeks prior to the first study dose

Prior autologous hematopoietic stem cell infusion \<4 weeks prior to first study dose

Grade 2 or greater unresolved toxicity from prior antineoplastic therapy

Grade 2 or greater peripheral neuropathy

Female participants who are both lactating and breastfeeding, or have a positive serum pregnancy test during the screening period or a positive urine pregnancy test on Day 1 before the first dose of study drug

Received local palliative radiation therapy \<14 days prior to the first dose of study medication

Received radiation therapy to more than 25% of the bone marrow-containing spaces \< 84 days prior to first dose of study medication

Received a strong or listed moderate inhibitor of CYP3A4 \<2 weeks prior to first study dose

Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study

What this study is about